Regarding the indication of the ICI treatment, ALT increase was shown to be more frequent among patients treated for HCC associated with chronic hepatitis or cirrhosis compared with those treated for non-liver cancers such as melanoma or non–small-cell lung cancer (Brown et al., 2017; Wolchok et al., 2017). This evidence concerns the gene GPT and hepatocellular carcinoma.